American Medical Systems?® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for both male and female pelvic health, announced today the company received CE (Conformite Europeenne) Mark for AdVance XP. Imitrex The device is the latest generation of AMS’ AdVance sling, a minimally invasive implant for the treatment of male stress urinary incontinence (SUI). Male SUI is an unfortunate and common side effect of prostate cancer and benign prostatic hyperplasia (BPH) treatments, such as radical prostatectomy and transurethral resection of the prostate (TURP).
Built on the trusted success of the AdVance platform, AdVance XP incorporates additional features that are designed to deliver Xtra Performance for improved ease-of-use and clinical outcomes. Enhancements include a redesigned sling that incorporates a new mesh designed to improve procedural reproducibility , longer arms that are easier to use in larger patients and distinct tissue anchors that increase holding power during the critical healing period, following implantation.
"With AdVance XP, we are solidifying our best-in-class male sling status," said Whitney Erickson, vice president and general manager for men’s health at AMS. "These enhanced features are designed to provide improvements to the AdVance male sling platform that lead to even greater reliability and procedural consistency."
The first AdVance XP implant was performed by Professor Francois Haab on July 12 at Tenon Hospital in Paris, France. "The AdVance XP sub-urethral sling is a substantial and positive evolution of the existing AdVance sling," Haab commented. "AdVance XP maximizes the already very satisfactory results that have been published with AdVance."
AMS has launched AdVance XP with a focused group of urologists throughout Europe with full-scale launch anticipated by the end of the year. AMS has filed for Food and Drug Administration (FDA) clearance. Pending required regulatory clearances, U.S. commercialization will commence.
SOURCE American Medical Systems, Inc.
Tags: Benign Prostatic Hyperplasia, Cancer, Erectile Dysfunction, Evolution, Hospital, Incontinence, Prostate Cancer, Prostatectomy, Radical Prostatectomy, Stress, Urinary Incontinence
Innovacell Biotechnologie commences enrollment in urocell Phase IIb study for bladder weakness"First patient in" is the call from the Innsbruck firm, Innovacell Biotechnologie AG, as the first p…Clinical abstracts on Urologix’ Cooled ThermoTherapy selected for presentation at AUA’s GUS meetingUrologix?®, Inc., a medical device company that develops, manufactures and markets minimally invasive…Robotic surgery does not compromise clinical outcomes for prostate cancer surgeryRobotic surgical technology with its three-dimensional, high-definition view gives surgeons the sens…Proteins found in intestines can recognize and kill bacteria that have human blood type moleculesA set of proteins found in our intestines can recognize and kill bacteria that have human blood type…BioMarin Pharmaceutical announces the acquisition of Huxley PharmaceuticalsBioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxl…Diet rich in fat, sugar and cholesterol a potential risk factor for Alzheimer’s diseaseMice that were fed a diet rich in fat, sugar and cholesterol for nine months developed a preliminary…Beginnings of complex life traced to microRNADartmouth College researchers and colleagues from the University of Bristol in the U.K. have traced …TV ads for drugs high on the emotions but low on factsAccording to a new study television commercials for prescription drugs are heavily loaded on the emo…Long-term oncologic outcomes: A 40 year radical prostatectomy single institution seriesSingle institution long-term outcomes for radical prostatectomy are scarce in the literature. In the…Increased attention should be paid to incontinenceIt’s a topic that is discussed so infrequently - for reasons that are easy to understand - that it m…Treatment of U.S. patients hospitalized for heart attacks continues to vary according to sex and raceDespite a decade of initiatives to remedy health disparities in cardiovascular medicine, at least so…
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Hong Kong S.A.R.
Macao S.A.R.
U.A.E.

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
between patient and physician/doctor and the medical advice they may provide.
Antibody Arthritis Biotechnology Bone Brain Breast Cancer Cancer Cardiovascular Disease Cell Chemotherapy Depression Diabetes Diet DNA Education Exercise Genetics Health and Human Services Health Insurance Health Reform Hospital Investment Medicaid Medicare Mental Health Nervous System New Drug Application Nursing Nutrition Obesity Oncology Pathology Pediatrics Prostate Cancer Psychology RNA Stress Stroke Vaccine Virus
U.N. says nearly 14M Pakistanis affected by floodsCuris announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancerInsurers to help doctors, hospitals buy health ITLentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanomaBellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous yearMeasurable medical errors cost U.S. economy $19.5 billion in 2008: ReportIsis second-quarter pro forma net operating loss increases to $15.5 millionAlso in Global Health News: Food production and climate change; Poverty and hunger in India; Composting toilets in MalawiEpitomics launches EP Clone Rabbit Monoclonal AntibodiesNew familial link in juvenile myelomonocytic leukemia discovered
Jobs in Nuclear MedicineRadiation DoseNuclear Medicine AnalysisSources of Radioisotopes for MedicineHistory of Nuclear MedicineNuclear Medicine ConcernsNuclear Medicine TechniquesNuclear Medicine - What is Nuclear Medicine?Pap Smear ProcedurePap Smear Effectiveness
This site complies with the HONcode standard for trustworthy health information:
verify here.